全球静脉血栓栓塞治疗市场规模、份额、成长分析，按设备（加压系统、血栓切除系统）、按应用（深部静脉栓塞、肺栓塞）-行业预测 2024-2031

2022年，全球静脉血栓栓塞治疗市场规模为11.2亿美元，预计将从2023年的12.2亿美元成长到2031年的23.7亿美元，在预测期（2024-2031年）复合年增长率为8.7% 。

静脉血栓栓塞 (VTE) 治疗市场涉及静脉内形成的血栓引起的严重医疗问题，并可能导致潜在致命的併发症，例如深部静脉栓塞或肺栓塞。市场以腹侧四肢瘫痪 (VTE) 的干预措施和治疗方案为中心，这是一个重大的全球健康问题。 VTE 治疗市场的动态由多个变数驱动。首先，VTE 发生次数的增加推动了对有效治疗的需求，这通常与久坐的生活方式、人口老化和手术技术有关。其次，与注射疗法和直接口服抗凝血剂（DOAC）等传统治疗方案相比，抗凝血药物的新发展提供了出血风险较低的先进治疗替代方案。由于人们对 VTE 危害的认识不断加深以及早期诊断和治疗的重要性，该市场正在不断扩大。由于采用创新的治疗策略和预防措施（包括机械压缩装置和过滤器），VTE 治疗市场也不断扩大。但管理 VTE 面临挑战，包括需要个别化的治疗方法、监测患者的依从性以及解决与抗凝血剂相关的出血性头痛的风险。随着 VTE 盛行率持续上升，VTE 治疗市场对于为面临或已患有这种疾病的患者提供挽救生命的干预措施和治疗计划至关重要。

目录

执行摘要

• 市场概况
• 命运之轮

研究方法论

• 资讯采购
• 二手和主要资料来源
• 市场规模估计
• 市场假设与限制

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战

主要市场洞察

• 技术分析
• 定价分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• 启动分析
• 原料分析
• 创新矩阵
• 管道产品分析
• 总体经济指标
• 顶级投资分析
• 成功的关键因素
• 竞争程度

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战
• 监管环境
• 波特分析
• 对未来颠覆的特别见解

按设备分類的全球静脉血栓栓塞治疗市场

• 市场概况
• 压缩系统
• 血栓切除系统
• 下腔静脉过滤器
• 丝袜
• 其他的

全球静脉血栓栓塞治疗市场（依应用）

• 市场概况
• 深层静脉栓塞
• 肺栓塞

全球静脉血栓栓塞治疗市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • MEA 的其余部分

竞争格局

• 前 5 名玩家比较
• 2023 年关键参与者的市场定位
• 主要市场参与者所采取的策略
• 最佳制胜策略
• 近期市集活动
• 主要公司市占率 (%), 2023

主要公司简介

• Bayer AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Johnson & Johnson
• Sanofi
• Daiichi Sankyo Company, Limited
• Aspen Pharmacare Holdings Limited
• Portola Pharmaceuticals, Inc. (Now part of Alexion Pharmaceuticals, Inc.)
• Leo Pharma A/S
• GlaxoSmithKline plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan NV (Now part of Viatris Inc.)
• Abbott Laboratories
• Biogenics Inc.
• Pfizer (Ireland) Pharmaceuticals
• CSL Limited
• Mitsubishi Tanabe Pharma Corporation
• Roche Holding AG

Global Venous Thromboembolism Treatment Market size was valued at USD 1.12 billion in 2022 and is poised to grow from USD 1.22 billion in 2023 to USD 2.37 billion by 2031, growing at a CAGR of 8.7% during the forecast period (2024-2031).

The market for treatments for venous thromboembolism (VTE) deals with a critical medical problem caused by blood clots that form inside veins and may cause potentially fatal complications such as deep vein thrombosis or pulmonary embolism. The market is centered around interventions and treatment options for ventral tetraplegia (VTE), which is a significant global health concern. The dynamics of the VTE treatment market are driven by multiple variables. First off, the need for efficient treatments is fueled by the rising number of VTE occurrences, which are frequently linked to sedentary lifestyles, aging populations, and surgical techniques. Second, compared to conventional treatment regimens like injection therapies and direct oral anticoagulants (DOACs), new developments in anticoagulant medications offer advanced therapy alternatives with fewer bleeding risks. The market is expanding due to growing knowledge of VTE hazard aspects and the importance of early diagnosis and treatment. The market for VTE therapy is also expanding as a result of the use of innovative treatment strategies, preventative measures, including mechanical compression devices and filters. But managing VTE presents challenges, including the need for individualized treatment approaches, monitoring patient adherence, and addressing the risk of bleeding headaches linked to anticoagulants. The market for VTE treatment is crucial in providing life-saving interventions and treatment plans to patients who are at danger of or already afflicted with this ailment, as the prevalence of VTE continues to rise.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Venous Thromboembolism Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Venous Thromboembolism Treatment Market Segmental Analysis

The Venous Thromboembolism Treatment Market is segmented by Device, Application, End-use, and Region. Based on Device the market is segmented as, Compression System, Thrombectomy Systems, IVC Filters, Stockings, Others. Based on Application the market is segmented as, Deep vein Thrombosis, Pulmonary Embolism. Based on End-use the market is segmented as, Hospitals, Catheterization Laboratories, Others. Regional the market is segmented as, North America, Europe, Asia-Pacific, and Latin America.

Drivers of the Global Venous Thromboembolism Treatment Market

Advancements in anticoagulant therapies, including direct oral anticoagulants (DOACs), are driving growth in the global VTE treatment market. These novel therapies offer advantages such as improved efficacy, safety profiles, and convenient oral administration compared to traditional therapies like warfarin, thereby increasing their adoption among patients and healthcare providers.

Restraints in the Global Venous Thromboembolism Treatment Market

Limited access to healthcare facilities and awareness in developing regions hinders the effective management of venous thromboembolism (VTE). In regions with inadequate healthcare infrastructure, patients may not receive timely diagnosis or treatment, leading to higher rates of morbidity and mortality associated with VTE.

Market Trends of the Global Venous Thromboembolism Treatment Market

The increasing prevalence of VTE among aging populations, coupled with rising incidences of risk factors such as obesity and sedentary lifestyles, is a significant market trend. As the population ages and lifestyles continue to change, the incidence of VTE is expected to rise globally, driving the demand for effective treatment options and preventive measures.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Venous Thromboembolism Treatment Market by Device

• Market Overview
• Compression System
• Thrombectomy Systems
• IVC Filters
• Stockings
• and Others

Global Venous Thromboembolism Treatment Market by Application

• Market Overview
• Deep vein Thrombosis
• Pulmonary Embolism

Global Venous Thromboembolism Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare Holdings Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Portola Pharmaceuticals, Inc. (Now part of Alexion Pharmaceuticals, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Now part of Viatris Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogenics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (Ireland) Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments